Cart
sales@molnova.com
N-(3-methoxyphenyl)prop-2-enamide
CAS No. 17208-99-0
N-(3-methoxyphenyl)prop-2-enamide ( —— )
Catalog No. M28406 CAS No. 17208-99-0
N-(3-methoxyphenyl)prop-2-enamide is a chemical compound.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 57 | Get Quote |
|
| 5MG | 87 | Get Quote |
|
| 10MG | 131 | Get Quote |
|
| 25MG | 224 | Get Quote |
|
| 50MG | 336 | Get Quote |
|
| 100MG | 503 | Get Quote |
|
| 500MG | 1107 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameN-(3-methoxyphenyl)prop-2-enamide
-
NoteResearch use only, not for human use.
-
Brief DescriptionN-(3-methoxyphenyl)prop-2-enamide is a chemical compound.
-
DescriptionN-(3-methoxyphenyl)prop-2-enamide is a chemical compound.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptorprotoporphyrinogen oxidase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number17208-99-0
-
Formula Weight177.2
-
Molecular FormulaC10H11NO2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCOc1cccc(NC(=O)C=C)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Mahmoudi M, Rahnemaie R, Es-haghi A, Malakouti MJ. Kinetics of degradation and adsorption-desorption isotherms of thiobencarb and oxadiargyl in calcareous paddy fields. Chemosphere. 2013 May;91(7):1009-17. doi: 10.1016/j.chemosphere.2013.01.077. Epub 2013 Feb 22. PubMed PMID: 23461836.
molnova catalog
related products
-
Esculentoside C
Esculentoside C exerts proinflammatory effects synergistically, it can induce inflammatory stimulation.
-
Caulilexin C
Caulilexin C shows inhibitory activity on human Acyl CoA: cholesterol transferase I (hACATI) and on human Acyl CoA: cholesterol transferase 2 (hACAT2) at 100 mug/ml.
-
Stressin I
Potent and selective corticotropin releasing factor receptor-1 (CRF1) agonist (Ki values are 1.5 and 224 nM for CRF1 and CRF2 receptors respectively). Increases ACTH levels and increases faecal pellet output in vivo following i.p. administration.
